Annovis Bio (ANVS) Q2 2026 earnings

Published Aug 14, 2026

AI summary

GAAP EPS −$0.40 beat the −$0.46 consensus by $0.06, down from −$0.32 a year ago.
Annovis Bio reported a net loss of $0.40 per share for the second quarter of 2026.
Research and development expenses rose to $12 million from $5.2 million in the prior year period.
The company fully enrolled its pivotal Phase 3 Alzheimer’s disease trial with 850 patients.
Cash and cash equivalents totaled $18.7 million as of June 30, 2026.

Revenue

Not reported in this release.

EPS · GAAP (street basis)

Reported · Diluted EPS (GAAP, street basis)

−$0.40

Consensus −$0.46

Beat by $0.06

GAAP EPS: −$0.40

Consensus: Yahoo Finance · Q2 2026 · EPS estimate at release
Revenue display rounded; difference uses exact result.

No guidance in this release.

The company reported a significant increase in operating expenses compared to the same quarter last year.
Total stockholders' equity turned negative as of June 30, 2026.

Source: Annovis Bio, Inc. press release · SEC Form 8-K exhibit 99.1

Figures as stated in the company’s release; consensus from the provider named above. Not financial advice.